Merck & Co., Inc. (MRK) — Analysis Summary
Merck & Co., Inc. (MRK) has a market cap of $308.90B with year-over-year revenue growth of +1.3%. Net margin stands at 28.1%. The stock trades at a P/E ratio of 34.6.
Key Takeaways
- Revenue changed +1.3% year-over-year
- Net margin of 28.1%
- P/E ratio of 34.6
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, MRK posted revenue growth of +1.3% and trades at a P/E of 34.6.
Merck & Co., Inc. (MRK)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at 0.0x — earnings do not cover interest payments
Net income fell 51.1% vs the prior period.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Sector
PHARMACEUTICAL PREPARATIONS
Employees
75,000
Headquarters
RAHWAY, NJ
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$3.40
Dividend Yield
2.72%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.